Bradley Fletcher, MD
Hematology & Oncology · Tampa, FLNPI 1427099423
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,746 of the $2,146 with a category attached, or 81.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 36 payments — averaging $59.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genetix Biotherapeutics Inc$500
- Vertex$400
- Sanofi$238
- Agios Pharmaceuticals, Inc.$170
- Global Blood Therapeutics, Inc.$125
- E.r. Squibb & Sons, L.L.C.$119
- plus $595 from 13 others
Across 19 payments — averaging $1555.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$30K
What the payments were for
- Consulting fees$40019%
- Food & beverage$1,74681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genetix Biotherapeutics Inc | 5 | $500 |
| Vertex | 1 | $400 |
| Sanofi | 3 | $238 |
| Agios Pharmaceuticals, Inc. | 3 | $170 |
| Global Blood Therapeutics, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Rigel Pharmaceuticals, Inc. | 1 | $114 |
| Novartis | 4 | $84 |
| Tempus AI, Inc | 3 | $71 |
| AstraZeneca | 3 | $62 |
| Bristol Myers Squibb | 1 | $51 |
| Pharmacosmos Therapeutics Inc. | 2 | $48 |
| Biomarin Pharmaceutical Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Caris MPI, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,146 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $31,064 |
| XareltoRivaroxaban | 11 | $12,710 |
| Imatinib Mesylate | 12 | $3,522 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.